Xencor, Inc. (XNCR)

Over the past six months, Xencor's stock has been influenced by key events. In October 2025, RBC Capital raised its price target on Xencor to $18, maintaining an "Outperform" rating, following promising Phase 1 data for XmAb819 in clear cell renal cell carcinoma (ccRCC). BofA also raised its price target to $15 in October 2025, keeping a "Neutral" rating. Earlier in September 2025, Xencor's shares fell after BofA Securities downgraded the stock from "Buy" to "Neutral," lowering the price target to $12.00. Cantor Fitzgerald initiated coverage with an "Overweight" rating and a $40.00 price target in October 2025, while Barclays assumed coverage with an "Underweight" rating and a $6.00 price target in September 2025.

As a clinical-stage biopharmaceutical company, Xencor's revenue primarily comes from collaboration, product licensing, and technology licensing agreements, rather than direct sales. Therefore, traditional demand seasonality is not directly applicable. Detailed information on seasonal patterns related to its stock returns is available through specialized financial tools, but this does not reflect seasonality in product demand.

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibodies and cytokines for cancer and autoimmune diseases, utilizing its proprietary XmAb® technology platform to enhance therapeutic properties. The company operates in the Healthcare sector, specifically within the Biotechnology and Pharmaceutical Products industry, leveraging its XmAb® protein engineering platform to create molecules with improved immune engagement, extended half-life, and multi-specificity. Xencor's pipeline includes clinical-stage product candidates such as XmAb819, XmAb541, XmAb808, and Vudalimab, along with other candidates like XmAb942, Plamotamab, XmAb564, and XmAb662; its technology has also contributed to marketed medicines through partnerships.

Xencor, Inc. is headquartered in Pasadena, California, United States. While it engages in collaborations and licensing agreements for global market reach, its primary operational footprint is concentrated in California.

Xencor's brand reputation has been shaped by positive clinical advancements and market adjustments. Promising Phase 1 data for XmAb819 in ccRCC boosted confidence, leading to "Buy" ratings and increased price targets in October 2025. However, a stock decline followed a BofA Securities downgrade in September 2025, and a report from April 2025 noted a significant stock plummet due to stalled progress. The company has since realigned its pipeline, focusing on lead T-cell engagers and autoimmune disease programs to rebuild momentum.

Major institutional investors in Xencor, Inc. include Essex LLC, SG Americas Securities LLC, Inspire Investing LLC, and the State of Alaska Department of Revenue. Individual insiders, such as Bassil I Dahiyat, John R Desjarlais, and others, also hold company stock.